Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04533191 · ClinicalTrials.gov registry record

Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)

A clinical trial of Cataract and Pseudophakia, sponsored by Vance Thompson Vision.

Completed
Registry status
25
Enrollment target
1
Study location

NCT04533191 is a study of Cataract and Pseudophakia that has completed, run by Vance Thompson Vision. The registered enrollment target is 25 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04533191, a study of Cataract and Pseudophakia, has completed, sponsored by Vance Thompson Vision.

COMPLETED
Registry status
25 participants
Enrollment target
1
Study location

Study Summary

The objective of this investigator initiated study (IIT-001) is to obtain data on clinical methods which can be used during the examination of patients desiring binocular custom vision with the Light Adjustable Lens (LAL). An analysis of the collected data will be performed to determine whether these clinical assessments can be used by doctors to enhance their patient's clinical outcome.

Conditions Studied

Interventions

  • PROCEDURE LAL IOL lens

Study Locations (1)

South Dakota

  • Vance Thompson Vision - Sioux Falls

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2020-09-01
Est. Completion 2021-02-01

Sponsor

Vance Thompson Vision

14 total trials

What the Registry Record Tells You About NCT04533191

The ClinicalTrials.gov registry entry for NCT04533191 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (89% lower). The listed sponsor is Vance Thompson Vision, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which LAL IOL lens is the first listed.

NCT04533191 reports 1 study location spanning 1 distinct geographic area - top geographies include South Dakota.

Frequently Asked Questions

What is clinical trial NCT04533191 about?

NCT04533191 is a clinical study titled "Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)". The objective of this investigator initiated study (IIT-001) is to obtain data on clinical methods which can be used during the examination of patients desiring binocular custom vision with the Light Adjustable Lens (LAL). An analysis of the collected data will be performed to determine whether thes...

What is the current status of trial NCT04533191?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2020-09-01. Estimated completion is 2021-02-01.

What conditions does trial NCT04533191 study?

This clinical trial studies the following conditions: Cataract, Pseudophakia.

What interventions are being tested in trial NCT04533191?

The interventions under investigation include: LAL IOL lens (PROCEDURE).

Who is sponsoring clinical trial NCT04533191?

This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04533191 being conducted?

This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.